14 jul. 2024
Cyclomics announces that co-founder Wigard Kloosterman will assume the role of Chief Executive Officer. Wigard brings extensive experience from both academia and biotechnology to drive Cyclomics’ mission of advancing liquid biopsy technology.
Cyclomics, a pioneering leader in molecular diagnostic solutions, is proud to announce that co-founder Wigard Kloosterman has taken on the role of Chief Executive Officer (CEO). This strategic leadership transition follows Wigard’s successful tenure at Frame Therapeutics – currently named CureVac Netherlands, after the acquisition by CureVac – where his innovative contributions and visionary leadership significantly propelled the company.
At Cyclomics, Wigard will leverage his vast experience at academia and commercial biotechnology to drive the company’s revolutionary vision for liquid biopsies. His extensive experience and passion for scientific innovation have been instrumental in Cyclomics’ development and growth thus far, and his full-time commitment is expected to further accelerate the company’s progress.
“Cyclomics is at the forefront of transforming how we detect and monitor diseases. I am excited to take on this new role and to work with our talented and multi-disciplinary team to push the boundaries of what is possible in disease diagnostics technology,” said Wigard Kloosterman. “Our mission is to make a significant impact on science and healthcare, and I am committed to leading our efforts towards sustainable growth and continued innovation.”
Co-founder Jeroen de Ridder added, “Wigard’s dedication and vision have been critical to our success. His transition to a full-time CEO marks a pivotal moment for Cyclomics as we continue to advance our technology and expand our impact in the diagnostics field.”
Alessio Marcozzi, R&D director and co-founder, shared his enthusiasm: “With Wigard at the helm, we are more confident than ever in our ability to bring groundbreaking solutions to the market. His leadership will undoubtedly steer us towards new heights in scientific achievement and business growth.”
Cyclomics extends its gratitude to Wigard Kloosterman for this unconditional commitment and innovative mindset. The entire team is excited about the path forward and confident in the company’s potential to make a profound impact on the cancer diagnostics landscape.